glp-1 vomiting lawsuit in michigan Ozempic Bariatric Surgery Vs. GLP-1: Which

Novo Nordisk denies that a causal relationship exists between its semaglutide products and NAION and has not updated its warning labels to include vision loss as a known risk

Summary Across the SURPASS clinical trials documented in the Mounjaro FDA prescribing information, injection-site reactions affected approximately 3-7% of participants depending on dose, while true systemic allergic reactions are rare

Compounded Liraglutide Starting at $115.00 1-month supply A once-daily GLP-1 injection

The FDA's April 30, 2026 proposal to exclude semaglutide from the 503B bulk substances list - currently in public comment through June 29, 2026 - would, if finalized, close large-scale outsourcing-facility compounding of semaglutide from bulk entirely

For brand-name options, it routes to a local pharmacy or through insurance